Literature DB >> 3415210

Comparative activities of several nucleoside analogs against influenza A, B, and C viruses in vitro.

S Shigeta1, K Konno, T Yokota, K Nakamura, E De Clercq.   

Abstract

A set of 20 nucleoside analogs were examined for their inhibitory effects on the cytopathogenicity and growth of influenza virus type A, B, and C strains in Madin-Darby canine kidney (MDCK) cells. Among the compounds evaluated, pyrazofurin, 3-deazaguanine, ribavirin, carbodine, and cyclopentenyl cytosine inhibited viral cytopathogenicity at concentrations that were lower than those found cytotoxic for the MDCK cells. No differences were observed in the 50% effective doses (based on inhibition of viral cytopathogenicity) of these five compounds for a number of influenza virus type A (subtypes H1N1 and H3N2), B, and C strains. Pyrazofurin showed the lowest 50% effective dose (0.15 microgram/ml), which was about 20- to 30-fold lower than those of the other four compounds. The selectivity indices of the five compounds, calculated as the ratio of the 50% cytotoxic dose (determined by trypan blue exclusion) to the 50% effective dose, were greater than 100. When the selectivity indices were calculated as the ratios of the 50% inhibitory doses for cellular RNA synthesis to the 50% effective doses, they were greater than 100 for ribavirin, pyrazofurin, and 3-deazaguanine but less than 2 for carbodine and cyclopentenyl cytosine. All five compounds inhibited the growth of influenza virus types A and B in MDCK cells at a concentration which was well below their cytotoxicity threshold for MDCK cells and, therefore, deserve further exploration for their potential in the treatment of influenza virus type A, B, and C infections.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3415210      PMCID: PMC172304          DOI: 10.1128/AAC.32.6.906

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  The broad spectrum antiviral agent ribavirin inhibits capping of mRNA.

Authors:  B B Goswami; E Borek; O K Sharma; J Fujitaki; R A Smith
Journal:  Biochem Biophys Res Commun       Date:  1979-08-13       Impact factor: 3.575

2.  Treatment of influenza A (H1N1) virus infection with ribavirin aerosol.

Authors:  S Z Wilson; B E Gilbert; J M Quarles; V Knight; H W McClung; R V Moore; R B Couch
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

3.  Antiviral activity of 3-deazaguanine, 3-deazaguanosine, and 3-deazaguanylic acid.

Authors:  L B Allen; J H Huffman; P Dan Cook; R B Meyer; R K Robins; R W Sidwell
Journal:  Antimicrob Agents Chemother       Date:  1977-07       Impact factor: 5.191

4.  Inhibitory effects of antiviral compounds on respiratory syncytial virus replication in vitro.

Authors:  F Kawana; S Shigeta; M Hosoya; H Suzuki; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

5.  Successful treatment of naturally occurring influenza A/USSR/77 H1N1.

Authors:  L P Van Voris; R F Betts; F G Hayden; W A Christmas; R G Douglas
Journal:  JAMA       Date:  1981-03-20       Impact factor: 56.272

6.  Evaluation of carbodine, the carbocyclic analog of cytidine, and related carbocyclic analogs of pyrimidine nucleosides for antiviral activity against human influenza Type A viruses.

Authors:  W M Shannon; G Arnett; L Westbrook; Y F Shealy; C A O'Dell; R W Brockman
Journal:  Antimicrob Agents Chemother       Date:  1981-12       Impact factor: 5.191

7.  Mechanism and specificity of action of ribavirin.

Authors:  M J Browne
Journal:  Antimicrob Agents Chemother       Date:  1979-06       Impact factor: 5.191

8.  Ribavirin treatment of experimental respiratory syncytial viral infection. A controlled double-blind study in young adults.

Authors:  C B Hall; E E Walsh; J F Hruska; R F Betts; W J Hall
Journal:  JAMA       Date:  1983-05-20       Impact factor: 56.272

9.  Ribavirin aerosol treatment of influenza B virus infection.

Authors:  H W McClung; V Knight; B E Gilbert; S Z Wilson; J M Quarles; G W Divine
Journal:  JAMA       Date:  1983-05-20       Impact factor: 56.272

10.  Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial.

Authors:  J C Wade; B Newton; C McLaren; N Flournoy; R E Keeney; J D Meyers
Journal:  Ann Intern Med       Date:  1982-03       Impact factor: 25.391

View more
  18 in total

1.  Activities of two new antiviral agents against guinea pig lymphotropic herpesvirus infection in vitro.

Authors:  J M Hu; G D Hsiung
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequences of the viral envelope glycoproteins.

Authors:  M Hosoya; J Balzarini; S Shigeta; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

Review 3.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

4.  Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4- carboxamide and related compounds.

Authors:  E De Clercq; M Cools; J Balzarini; R Snoeck; G Andrei; M Hosoya; S Shigeta; T Ueda; N Minakawa; A Matsuda
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

5.  Inhibitory effect of a nucleotide analog on infectious salmon anemia virus infection.

Authors:  Andrea Rivas-Aravena; Eva Vallejos-Vidal; Marcelo Cortez-San Martin; Felipe Reyes-Lopez; Mario Tello; Patricia Mora; Ana María Sandino; Eugenio Spencer
Journal:  J Virol       Date:  2011-06-08       Impact factor: 5.103

6.  Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro.

Authors:  T Yokota; K Konno; E Chonan; S Mochizuki; K Kojima; S Shigeta; E de Clercq
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

7.  Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis.

Authors:  T Yokota; S Mochizuki; K Konno; S Mori; S Shigeta; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

8.  In vitro and in vivo inhibition of ortho- and paramyxovirus infections by a new class of sulfonic acid polymers interacting with virus-cell binding and/or fusion.

Authors:  S Ikeda; J Neyts; S Verma; A Wickramasinghe; P Mohan; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

9.  The pyrimidin analogue cyclopentenyl cytosine induces alloantigen-specific non-responsiveness of human T lymphocytes.

Authors:  N Nikolaeva; F J Bemelman; S-L Yong; A Verschuur; R A W van Lier; I J M ten Berge
Journal:  Clin Exp Immunol       Date:  2007-12-06       Impact factor: 4.330

10.  Effects of protease inhibitors on replication of various myxoviruses.

Authors:  M Hosoya; S Matsuyama; M Baba; H Suzuki; S Shigeta
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.